Five Prime Therapeutics

So sollen die Übernahmeverhandlungen abgelaufen sein. https://www.benzinga.com/general/biotech/21/03/20258498/though-potential-bidders-moved-away-amgens-bid-for-five-prime-outlasted-15-suitors

Amgen übernimmt FPRX in einem 1,9 Mrd. $ Deal

• 38$ Cash pro Aktie
  
• AMGN zahlt 78% Premium
  

https://www.fiercebiotech.com/biotech/amgen-pays-a-premium-for-five-prime-therapeutics-a-1-9b-cash-deal

Den Anstieg am 11. November hat ein großer Fonds zum Ausstieg genutzt: https://www.gurufocus.com/stock/FPRX/insider?search=five%20prime

142 Mio. $ Offering

Das ist ein 1A Offering, gutes Pricing und sogar noch upsized.

• 7,2 Mio. neue Aktien zu je 21$
  
• Option auf weitere 15%
  

"Five Prime plans to use the net proceeds of the offering, together with other available funds, to fund ongoing clinical development of bemarituzumab and FPT155, to advance FPA157 through preclinical and into clinical development, to advance its late-stage research programs and for working capital and general corporate purposes."

https://investor.fiveprime.com/news-releases/news-release-details/five-prime-announces-pricing-upsized-public-offering-common-0